How much alcohol should we infuse in the coronary artery of hypertrophic cardiomyopathy patients?

Journal of Invasive Cardiology

Volumn 22, Issue 1, 2010, Pages 22-26

  Aqel, Raed ^a,b   Hage, Fadi G ^a,b   Aljaroudi, Wael ^a,b   Lawson, David ^a,b   Sweeney, Aaron ^a,b   Hansalia, Sachin ^a,b   Pothineni, Koteswara ^a,b   Heo, Jaekyeong ^a,b   Pajaro, Octavio ^a,b   McGiffin, David ^a,b   Dell'Italia, Louis ^a,b   Iskandrian, Ami E ^a,b  

^a University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Alcohol septal ablation; Infarct mass; Left ventricular outflow gradient

Indexed keywords

ALCOHOL;

ALCOHOL SEPTAL ABLATION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DOPPLER ECHOCARDIOGRAPHY; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART MUSCLE PERFUSION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGING; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PROVOCATION;

ABLATION TECHNIQUES; ADULT; AGED; CARDIOMYOPATHY, HYPERTROPHIC; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY, DOPPLER; ETHANOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL PERFUSION IMAGING; RETROSPECTIVE STUDIES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 76849110407     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Ramaraj R. Hypertrophic cardiomyopathy: Etiology, diagnosis, and treatment. Cardiology in review 2008;16:172-180.
2. Ommen SR, Shah PM, Tajik AJ. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: past, present and future. Heart (British Cardiac Society) 2008;94:1276-1281.
3. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348:295-303.
4. Autore C, Bernabo P, Barilla CS, et al. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol 2005;45:1076-1080.
5. Elliott PM, Gimeno JR, Tome MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006;27:1933-1941.
6. Alam M, Dokainish H, Lakkis N. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A systematic review of published studies. J Intervent Cardiol 2006;19:319-327.
7. Knight CJ. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Heart (British Cardiac Society) 2006;92:1339-1344.
8. Veselka J. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A review of the literature. Med Sci Monit 2007;13: RA62-A68.
9. Holmes DR Jr, Valeti US, Nishimura RA. Alcohol septal ablation for hypertrophic cardiomyopathy: Indications and technique. Catheter Cardiovasc Interv 2005;66:375-389.
10. Aqel RA, Hage FG, Zohgbi GJ, et al. Serial evaluations of myocardial infarct size after alcohol septal ablation in hypertrophic cardiomyopathy and effects of the changes on clinical status and left ventricular outflow pressure gradients. Am J Cardiol 2008;101:1328-1333.
11. Sasson Z, Yock PG, Hatle LK, et al. Doppler echocardiographic determination of the pressure gradient in hypertrophic cardiomyopathy. J Am Coll Cardiol 1988;11:752-756.
12. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet. 2004;363:1881-1891.
13. Olivotto I, Ommen SR, Maron MS, et al. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? J Am Coll Cardiol 2007;50:831-834.
14. Seggewiss H, Rigopoulos A, Welge D, et al. Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 2007;96:856-863.
15. Maron BJ, Dearani JA, Ommen SR, et al. The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;44:2044-2043.
16. Sorajja P, Valeti U, Nishimura RA, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2008;118:131-139.
17. Kuhn H, Lawrenz T, Lieder F, et al. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): A 10 year experience. Clin Res Cardiol 2008;97:234-243.
18. Cuoco FA, Spencer WH 3rd, Fernandes VL, et al. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol 2008;52:1718-1723.
19. Pauschinger M, Keren A. Increasing evidence for the safety and efficacy of alcohol septal ablation during medium-and long-term follow-up. Clin Res Cardiol 2007;96:851-855.
20. Fernandes VL, Nagueh SF, Wang W, et al. A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy - The Baylor experience (1996-2002). Clinical Cardiol 2005;28:124-130.
21. Veselka J, Prochazkova S, Duchonova R, et al. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: Lower alcohol dose reduces size of infarction and has comparable hemodynamic and clinical outcome. Catheter Cardiovasc Interv 2004;63:231-235.
22. Veselka J, Duchonova R, Prochazkova S, et al. Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes. Am J Cardiol 2005;95:675-678.
23. Veselka J, Duchonova R, Palenickova J, et al. Impact of ethanol dosing on the long-term outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy: A single-center prospective, and randomized study. Circ J 2006;70:1550-1552.
24. Veselka J, Zemanek D, Tomasov P, et al. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: Ultra-low dose of alcohol (1 ml) is still effective. Heart and Vessels 2009;24:27-31.
25. Gibbons RJ, Miller TD, Christian TF. Infarct size measured by single photon emission computed tomographic imaging with (99m) Tc-sestamibi: A measure of the efficacy of therapy in acute myocardial infarction. Circulation 2000;101:101-108.